Daily non-political popular news in brief.

New genomic tests guide choice of chemotherapy in cancer patients

Scientists at Duke University's Institute for Genome Sciences & Policy have developed a panel of genomic tests that analyzes the unique molecular traits of a cancerous tumor and determines which chemotherapy will most aggressively attack that patient's cancer.

Read more »

Keywords: genomic, tests, guide, choice, chemotherapy, cancer, patients, test, patient

« Previous | Next »

Similar news on "New genomic tests guide choice of chemotherapy in cancer patients":

1. Mouse Tests Predict Drug Response In Relapsing Pancreatic Cancer Patients
   10-12-2006 · ScienceDaily
   By slicing up bits of patient tumors and grafting them into mice, Johns Hopkins Kimmel Cancer Center specialists have figured out how to accurately 'test drive' chemotherapy drugs to learn in advance which drug treatments offer each individual pancreatic cancer patient the best therapeutic journey.
   Similar news · Read more »
   
2. Mouse tests predict drug response in relapsing pancreatic cancer patients
   10-11-2006 · EurekAlert!
   By slicing up bits of patient tumors and grafting them into mice, Johns Hopkins Kimmel Cancer Center specialists have figured out how to accurately "test drive" chemotherapy drugs to learn in advance which drug treatments offer each individual pancreatic cancer patient the best therapeutic journey.
   Similar news · Read more »
   
3. Pre-treatment blood test could guide lung cancer therapy
   06-05-2007 · EurekAlert!
   A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has developed a new pre-treatment blood test that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies (Iressa, Tarceva). The mass spectrometry-based test, described in the June 6 Journal of the National Cancer Institute, may allow physicians to select the most beneficial therapy for each lung cancer patient, a step forward in the era of personalized medicine.
   Similar news · Read more »
   
4. Microarray provides 3 genomic guides to breast cancer treatment decisions
   09-06-2007 · EurekAlert!
   Three genomic tests separately predict the likelihood that a patient's breast cancer will reoccur after surgery without additional treatment, and the cancer's vulnerability to chemotherapy or hormone therapy, researchers at the University of Texas M. D. Anderson Cancer Center report at the first American Society of Clinical Oncology ASCO Breast Cancer Symposium, Sept. 7-8, in San Francisco.
   Similar news · Read more »
   
5. Genomic tests improve prediction of breast cancer response to chemotherapy, hormonal therapy
   12-14-2006 · EurekAlert!
   Researchers at the University of Texas M. D. Anderson Cancer Center have developed two genomic tests to better predict how breast cancer patients will respond to chemotherapy or hormonal therapy.
   Similar news · Read more »
   
6. FDG-PET imaging clearly predicts lung cancer patients' response to chemotherapy
   05-09-2007 · EurekAlert!
   An earlier indication of whether chemotherapy benefits non-small cell lung cancer patients -- provided by positron emission tomography (PET) imaging -- can guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.
   Similar news · Read more »
   
7. Radiation preferred over surgery for patients with some stages of lung cancer
   03-20-2007 · EurekAlert!
   After an initial chemotherapy treatment, radiation may be a better choice than surgery for patients with stage IIIA non-small-cell lung cancer, according to a randomized controlled trial published in the March 21 Journal of the National Cancer Institute. The authors suggest that a combination of chemotherapy and radiation should be the preferred treatment option for these patients.
   Similar news · Read more »
   
8. Study identifies characteristics of clinicians likely to order inappropriate prostate screenings
   07-09-2007 · EurekAlert!
   Prostate-specific antigen tests to screen for prostate cancer are frequently performed among patients for whom the PSA test is not shown to be beneficial, and clinicians with certain characteristics are more likely to order such inappropriate screening tests, according to a report in the July 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
   Similar news · Read more »
   
9. Report calls for using heated chemotherapy after colon cancer surgery to optimize patient survival
   11-03-2006 · EurekAlert!
   There is new hope for some of the most seriously ill colon cancer patients today, following the release of a consensus statement by 72 leading oncology surgeons from 14 countries, including the United States. The Peritoneal Surface Malignancy Group (PSMG) has concluded that surgery, followed by heated chemotherapy delivered through the lower abdomen of the patient before leaving the operating room, may significantly increase the life expectancy for patients with Stage IV colorectal cancer.
   Similar news · Read more »
   
10. Preventing graft-vs.-host disease after bone marrow transplant -- without toxicity
    12-11-2006 · EurekAlert!
    Most patients undergoing bone-marrow transplant must receive powerful chemotherapy drugs to suppress their immune system and prevent their bodies from rejecting the donated cells. New research shows that this chemotherapy increases the risk for graft-versus-host disease -- but also suggests that this risk can be reduced by replacing a natural antibiotic that's depleted when patients undergo chemotherapy. A multicenter study led by Children's Hospital Boston and the Dana-Farber Cancer Institute is about to test this idea.
    Similar news · Read more »